2023
Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
Gottlieb J, Fischer B, Schupp J, Golpon H. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors. PLOS ONE 2023, 18: e0284653. PMID: 37200246, PMCID: PMC10194991, DOI: 10.1371/journal.pone.0284653.Peer-Reviewed Original ResearchConceptsCNI-free immunosuppressionCalcineurin inhibitor-free immunosuppressionMTOR inhibitorsFree immunosuppressionLung transplantationImproved survivalRapamycin inhibitorsNeurological diseasesSingle-center case-control studyCenter case-control studyCNI-free regimenCurative treatment optionGlomerular filtration rateMajority of patientsNon-malignant indicationsSignificant functional improvementCase-control studyMechanistic targetAcute rejectionLTx patientsNeurological complicationsAdult patientsMedian durationSingle centerTreatment options
2020
Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome
Morrone C, Smirnova NF, Jeridi A, Kneidinger N, Hollauer C, Schupp JC, Kaminski N, Jenne D, Eickelberg O, Yildirim AÖ. Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome. European Respiratory Journal 2020, 57: 2001416. PMID: 33303550, DOI: 10.1183/13993003.01416-2020.Peer-Reviewed Original ResearchConceptsBronchoalveolar lavage fluidCathepsin B activityHealthy donorsLung tissueCollagen depositionB activityCathepsin BBronchiolitis obliterans syndromeProgression of BOSFluorescence resonance energy transfer-based assayPromising therapeutic targetGrowth factor-β1Cathepsin B levelsSubsequent collagen depositionBOS pathogenesisBOS patientsBOS progressionLTx patientsLymphocytic bronchiolitisObliterans syndromeLung transplantationPeribronchial fibrosisPulmonary dysfunctionLung functionMajor complications